$OTLKW News

Last published 1mo ago

1mo agoOTLK OTLKWOutlook Therapeutics Names Greg DiPasquale Chief Commercial OfficerGlobeNewswireISELIN, N.J., Oct. 09, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company focused on the development and commercialization of LYTENAVA™ (bevacizumab-vikg, bevacizumab gamma)
1mo agoOTLK OTLKWOutlook Therapeutics Highlights What the Appointment of New CFO Kevin Lundquist Means for the Company’s Next Chapter in Virtual Investor DiscussionGlobeNewswireSegment features Kevin Lundquist discussing his decision to join Outlook Therapeutics and the Company’s path forward following the FDA approval of LYTENAVA™ Access the segment here ISELIN, N.J., Oct. 06, 2026 (GLOBE
2mo agoOTLK OTLKWOutlook Therapeutics CEO, Bob Jahr, Discusses FDA Approval and Commercial Opportunity for LYTENAVA™ in Virtual Investor CEO Connect SegmentGlobeNewswireAccess the segment here ISELIN, N.J., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company focused on the development and commercialization of LYTENAVA™
2mo agoOTLK OTLKWOutlook Therapeutics Appoints Kevin Lundquist as Chief Financial Officer as It Prepares for U.S. Commercial Launch of LYTENAVA™GlobeNewswireSeasoned finance executive brings more than 20 years of leadership experience across global commercial organizations, including the pharmaceutical and medical technology industriesDeep expertise spans commercial
2mo agoOTLK OTLKWOutlook Therapeutics CEO, Bob Jahr, Participates in the Virtual Investor “Why Now” On-Demand ConferenceGlobeNewswireVideo webcast now available here ISELIN, N.J., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company focused on the development and commercialization of LYTENAVA™
2mo agoOTLK OTLKWOutlook Therapeutics Reports Third Quarter Fiscal Year 2026 Financial Results and Provides Business Update Highlighting FDA Approval of LYTENAVA™GlobeNewswireThe only FDA-approved ophthalmic bevacizumab, LYTENAVATM, addresses a significant need in the U.S. wet AMD market where bevacizumab is already widely used Advancing the U.S. launch strategy for LYTENAVA, including
3mo agoOTLK OTLKWOutlook Therapeutics Announces Pricing of $55.0 Million Public Offering of Common Stock and WarrantsGlobeNewswireISELIN, N.J., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK) ("Outlook Therapeutics"), a biopharmaceutical company focused on the development and commercialization of LYTENAVA™
3mo agoOTLK OTLKWOutlook Therapeutics Announces Proposed Public Offering of Common Stock and WarrantsGlobeNewswireISELIN, N.J., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK) ("Outlook Therapeutics"), a biopharmaceutical company focused on the development and commercialization of LYTENAVA™
3mo agoOTLK OTLKWOutlook Therapeutics to Report Third Quarter Fiscal Year 2026 Financial Results and Host a Corporate Update Conference Call and Webcast on August 14, 2026GlobeNewswireISELIN, N.J., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company focused on the development and commercialization of LYTENAVA™ (bevacizumab-vikg, bevacizumab gamma)
3mo agoOTLK OTLKWOutlook Therapeutics Announces LYTENAVA™ FDA Approval as the First and Only FDA-Approved Ophthalmic Bevacizumab for the Treatment of Wet AMDGlobeNewswireLandmark FDA Approval Is an Important Milestone in Retina Care, Bringing Patients and Physicians an Ophthalmic Bevacizumab Developed Specifically for the Eye Following Years of Rigorous Clinical and Regulatory
4y agoABC OTLK OTLKWOutlook Therapeutics® and AmerisourceBergen Announce Strategic Commercialization Agreement for ONS-5010 for the Treatment of Wet AMDGlobeNewswireISELIN, N.J. and CONSHOHOCKEN, Pa., Sept. 27, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK), a pre-commercial biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for
4y agoOTLK OTLKWOutlook Therapeutics® to Present at Eyecelerator @ AAO 2022GlobeNewswireISELIN, N.J., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK), a pre-commercial biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indicati
4y agoOTLK OTLKWOutlook Therapeutics® to Present at the H.C. Wainwright 24th Annual Global Investment ConferenceGlobeNewswireISELIN, N.J., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK), a pre-commercial biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indicati
4y agoOTLK OTLKWOutlook Therapeutics® Re-Submits Biologics License Application for ONS-5010 as a Treatment for Wet AMD to the U.S. Food and Drug AdministrationGlobeNewswireISELIN, N.J., Aug. 30, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today an
4y agoOTLK OTLKWOutlook Therapeutics Strengthens Board of Directors with Appointment of Julia A. Haller, MDGlobeNewswireISELIN, N.J., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK), a pre-commercial biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indicatio
4y agoOTLK OTLKWOutlook Therapeutics Reports Financial Results for Third Quarter Fiscal Year 2022 and Reiterates Key Anticipated Near-Term MilestonesGlobeNewswirePlanned re-submission of ONS-5010 / LYTENAVA™ (bevacizumab-vikg) Biologics License Application (BLA) to U.S. Food and Drug Administration (FDA) on track ISELIN, N.J., Aug. 10, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK)
4y agoOTLK OTLKWOutlook to Present at the H.C. Wainwright 2nd Annual Ophthalmology ConferenceGlobeNewswireISELIN, N.J., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK), a pre-commercial biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indicatio
4y agoOTLK OTLKWOutlook Therapeutics Announces Full Cash Pre-Payment of Convertible Promissory NoteGlobeNewswireISELIN, N.J., July 05, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK), a pre-commercial biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indica
4y agoOTLK OTLKWOutlook Therapeutics Confirms Status of Biologics License Application (BLA) Submission for ONS-5010GlobeNewswireOutlook Therapeutics reiterates expected re-submission of BLA by September 2022 following receipt of additional correspondence from U.S. Food and Drug Administration (FDA) ISELIN, N.J., June 14, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc
4y agoOTLK OTLKWOutlook Therapeutics Provides Update on Biologics License Application (BLA) Submission for ONS-5010 as a Treatment for Wet AMDGlobeNewswireISELIN, N.J., May 31, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK), a pre-commercial biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indicat
4y agoOTLK OTLKWOutlook Therapeutics to Present at the H.C. Wainwright Global Investment ConferenceGlobeNewswireISELIN, N.J., May 18, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK), a pre-commercial biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indication
4y agoOTLK OTLKWOutlook Therapeutics Reports Financial Results for Second Quarter Fiscal Year 2022 and Provides Corporate UpdateGlobeNewswireONS-5010 / LYTENAVA™ (bevacizumab-vikg) Biologics License Application (BLA) submitted to U.S. Food and Drug Administration (FDA); PDUFA date expected to be announced in June 2022 Advancing ONS-5010 toward potential marketing approval in early 2023 U
4y agoOTLK OTLKWOutlook Therapeutics to Participate in Retina World Congress 2022GlobeNewswireISELIN, N.J., May 10, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK), a pre-commercial biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indication
4y agoOTLK OTLKWOutlook Therapeutics to Participate at the Virtual Investor 2022 CEO SpotlightGlobeNewswireISELIN, N.J., May 09, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK), a pre-commercial biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indicat
4y agoOTLK OTLKWBioLexis Reorganization Results in GMS Holdings as Largest Shareholder in Outlook TherapeuticsGlobeNewswireSINGAPORE and ISELIN, N.J., April 22, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK), a pre-commercial biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in
4y agoOTLK OTLKWOutlook Therapeutics to Present at Wet AMD and DME Drug Development SummitGlobeNewswireISELIN, N.J., April 05, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today anno
4y agoOTLK OTLKWOutlook Therapeutics Bolsters Commercialization Expertise with Appointment of Alicia Tozier as Senior Vice President of Marketing and Market AccessGlobeNewswireMs. Tozier has held commercial leadership positions across the full product lifecycle and exceeded goals for 14 launches across 70-plus global markets, with deep experience in ophthalmology and leadership for launching wet AMD/DME therapies. ISELIN,
4y agoOTLK OTLKWOutlook Therapeutics to Present at the RANZCO 52nd Annual Scientific CongressGlobeNewswireISELIN, N.J., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today an
4y agoOTLK OTLKWOutlook Therapeutics Reports Financial Results for First Quarter Fiscal Year 2022 and Provides Corporate UpdateGlobeNewswireOutlook Therapeutics remains on track to submit new U.S. FDA Biologics License Application (BLA) for first ophthalmic formulation of bevacizumab Commercial launch planning underway Financed through the anticipated approval of the ONS-5010 BLA
4y agoOTLK OTLKWOutlook Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare ConferenceGlobeNewswireISELIN, N.J., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today an
4y agoOTLK OTLKWOutlook Therapeutics Expands Commercial Team with Appointment of Senior Vice President of Commercial OperationsGlobeNewswireJoel Prieve brings nearly 20 years of commercial operations expertise and proven track record in sales and account management ISELIN, N.J., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company
4y agoOTLK OTLKWOutlook Therapeutics to Present at the Fourth Annual Telluride Retina Film FestivalGlobeNewswireISELIN, N.J., Feb. 02, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today an
4y agoOTLK OTLKWOutlook Therapeutics Provides a Corporate Update and Business OutlookGlobeNewswireOutlook Therapeutics advancing first ever ophthalmic formulation of bevacizumab towards new U.S. FDA Biologics License Application (BLA) submission, anticipated this quarter ONS-5010 / LYTENAVA™ (bevacizumab-vikg) expected to receive, if approved, 12
4y agoOTLK OTLKWOutlook Therapeutics to Present at the Virtual Investor 2022 Top Picks ConferenceGlobeNewswireISELIN, N.J., Jan. 19, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today an
4y agoOTLK OTLKWOutlook Therapeutics to Present at the H.C. Wainwright BioConnect ConferenceGlobeNewswireISELIN, N.J., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today
4y agoOTLK OTLKWOutlook Therapeutics Reports Financial Results for Fiscal Year 2021 and Provides Corporate UpdateGlobeNewswirePositive clinical data reported for ONS-5010 / LYTENAVA™ (bevacizumab-vikg) in 2021 from multiple clinical trials, including statistically significant top-line efficacy and safety data from pivotal Phase 3 NORSE TWO trial for wet age-related macular d
4y agoOTLK OTLKWOutlook Therapeutics to Present Pivotal Data from NORSE TWO Trial at the 9th International Congress on OCT and OCT Angiography in Rome (ICOOR)/ FLORetina SymposiaGlobeNewswireISELIN, N.J., Dec. 15, 2021 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today an
4y agoOTLK OTLKWOutlook Therapeutics to Present at the 14th Asia-Pacific Vitreo-Retina Society (APVRS) CongressGlobeNewswireISELIN, N.J., Dec. 09, 2021 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today an
4y agoOTLK OTLKWOutlook Therapeutics Announces Closing of $57.5 Million Bought Deal, Including Full Exercise of Underwriter's Option to Purchase Additional SharesGlobeNewswireISELIN, N.J., Nov. 29, 2021 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK) ("Outlook Therapeutics"), a late clinical-stage biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of beva
4y agoOTLK OTLKWOutlook Therapeutics Increases Previously Announced Bought Deal Offering of Common Stock to $50 MillionGlobeNewswireISELIN, N.J., Nov. 23, 2021 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK) ("Outlook Therapeutics"), a late clinical-stage biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bev
4y agoOTLK OTLKWOutlook Therapeutics Announces $10 Million Bought Deal Offering of Common StockGlobeNewswireISELIN, N.J., Nov. 23, 2021 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK) ("Outlook Therapeutics"), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic formulation of bevacizumab-vik
4y agoOTLK OTLKWOutlook Therapeutics Presents NORSE TWO Phase 3 Pivotal Safety and Efficacy Data for ONS-5010 / LYTENAVA™ (bevacizumab-vikg) at the Retina Subspecialty Day, American Academy of Ophthalmology (AAO) 2021 Annual ConferenceGlobeNewswire- NORSE TWO showed highly statistically significant, clinically relevant results consistent with historical ophthalmic bevacizumab data - Data support planned BLA submission with U.S. FDA in Q12022 ISELIN, N.J., Nov. 13, 2021 (GLOBE NEWSWIRE) --
5y agoOTLK OTLKWOutlook Therapeutics to Present at the Virtual Investor Roundtable EventGlobeNewswireISELIN, N.J., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today an
5y agoOTLK OTLKWOutlook Therapeutics to Present at the Retina Subspecialty Day, American Academy of Ophthalmology 2021 Annual ConferenceGlobeNewswireISELIN, N.J., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today an
5y agoOTLK OTLKWOutlook Therapeutics to Present at the Eyecelerator@AAO 2021 Conference Retina ShowcasesGlobeNewswireISELIN, N.J., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today an
5y agoOTLK OTLKWOutlook Therapeutics' Positive NORSE THREE Safety Data Presented at 2021 American Society of Retina Specialists for ONS-5010 Ophthalmic BevacizumabGlobeNewswireISELIN, N.J., Oct. 12, 2021 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today pr
5y agoOTLK OTLKWOutlook Therapeutics to Present at the 2021 American Society of Retina Specialists (ASRS) Annual MeetingGlobeNewswireISELIN, N.J., Oct. 07, 2021 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today
5y agoOTLK OTLKWOutlook Therapeutics to Present at the Ophthalmology Innovation Summit (OIS) Retina Innovation ShowcaseGlobeNewswireISELIN, N.J., Oct. 05, 2021 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today
5y agoOTLK OTLKWOutlook Therapeutics Reports New Positive 12-Month Safety Data from Pivotal Phase 3 NORSE TWO TrialGlobeNewswireFull year data reinforce strong safety profile consistent with previous trials of ONS-5010 and with prior published data on ophthalmic bevacizumab Full data to be presented at American Academy of Ophthalmology's Retina Subspecialty Meeting, RET13 - Se
5y agoOTLK OTLKWOutlook Therapeutics to Present at the Cantor Fitzgerald Virtual Global Healthcare ConferenceGlobeNewswireISELIN, N.J., Sept. 21, 2021 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, toda